APMONIA THERAPEUTICS
Apmonia Therapeutics developing a pipeline of next generation peptide based therapies targeting the tumor microenvironment to improve the lives of patients with cancer. If anyone would want to contact them please contact them via phone call or email.
APMONIA THERAPEUTICS
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2019-01-01
Address:
Reims, Champagne-Ardenne, France
Country:
France
Website Url:
http://www.apmonia-therapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+33 3 26 91 89 84
Email Addresses:
[email protected]
Total Funding:
5.2 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Google Font API WordPress Google Maps Font Awesome Sitelinks Search Box Yoast WordPress SEO Plugin Person Schema
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
VIVAN Therapeutics
VIVAN Therapeutics is a company pioneering personalized cancer therapeutics using a new assay technology.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Probionova
Probionova is a research company that develops and provides probiotic strains and premixes for pharmaceuticals and nutraceuticals.
Current Advisors List
Current Employees Featured
Founder
Investors List
France 2030
France 2030 investment in Grant - Apmonia Therapeutics
Bpifrance
Bpifrance investment in Venture Round - Apmonia Therapeutics
Official Site Inspections
http://www.apmonia-therapeutics.com Semrush global rank: 14.22 M Semrush visits lastest month: 59
- Host name: cluster027.hosting.ovh.net
- IP address: 54.36.91.62
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Apmonia Therapeutics"
About us - Apmonia therapeutics
Apmonia Therapeutics was founded in 2019 as spin-off of CNRS and Reims university (UMR 7369 MEDyC). Executive team now gathers together members with decades of experience in …See details»
Apmonia Therapeutics - Crunchbase Company Profile & Funding
Apmonia Therapeutics developing a pipeline of next generation peptide based therapies targeting the tumor microenvironment to improve the lives of patients with cancer. If anyone would want …See details»
Apmonia Therapeutics Company Profile 2024: …
Apmonia Therapeutics has raised $7.24M. Who are Apmonia Therapeutics’s investors? European Innovation Council Fund , Bpifrance , Angels Santé , Capital Grand Est , and Finovam Gestion are 5 of 7 investors who have invested in …See details»
Apmonia Therapeutics - VentureRadar
Apmonia Therapeutics is a biotechnology company based in Reims (France) dedicated to the development of anti-cancer therapies. Building on renowned expertise in oncology as well as …See details»
Apmonia Therapeutics - Funding, Financials, Valuation & Investors
Apmonia Therapeutics is a biotech company that develops therapeutic strategies for cancer. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ...See details»
Apmonia Therapeutics - LinkedIn
Apmonia Therapeutics | 2,976 followers on LinkedIn. Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. | …See details»
Apmonia Therapeutics - Company Profile - Tracxn
Nov 28, 2024 Apmonia Therapeutics. has raised a total funding of $7.62M over 4 rounds. Its first funding round was on Feb 11, 2022. What are the most recent funding rounds of Apmonia …See details»
Apmonia Therapeutics - Tech Stack, Apps, Patents & Trademarks
Nov 10, 2024 Apmonia Therapeutics is a biotech company that develops therapeutic strategies for cancer.See details»
Apmonia Therapeutics - Products, Competitors, Financials, …
Apmonia Therapeutics on LinkedIn: Apmonia Tx - Press release EIC Accelerator 20240717. Jul 22, 2024. 🚨 PRESS RELEASE 🚨 Apmonia Therapeutics to receive €2.5m grant and €7m equity …See details»
Apmonia Therapeutics - French Healthcare Corner JP …
Founded in 2019 as a spin-off of CNRS and Reims University (UMR 7369 MEDyC), Apmonia Therapeutics is a biotechnology company at the forefront of anti-cancer immunotherapy. Boasting an executive team comprised of …See details»
Pipeline - Apmonia therapeutics
Pipeline AP-01 Apmonia Therapeutics’ lead program is a peptide-based technology, named AP-01 or TAX2, targeting tumor-overexpressed thrombospondin-1 (TSP-1) in order to prevent …See details»
Apmonia Therapeutics announces a €2.5 million financing to …
Apmonia Therapeutics' initial program, named AP-01, involves the use of a peptide (TAX2) that acts as a modulator of the tumor microenvironment, reprogramming vascularized tumors to …See details»
Apmonia Therapeutics - Contacts, Employees, Board Members
Organization. Apmonia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Number of …See details»
Science & technology - Apmonia therapeutics
Apmonia Therapeutics’ peptide-based technology named AP-01 (or TAX2 peptide) acts as an orthosteric selective antagonist for thrombospondin-1 (TSP-1) binding to CD47 membrane …See details»
Grant - Apmonia Therapeutics - 2024-07-15 - Crunchbase
Jul 15, 2024 Organization Name . Apmonia Therapeutics . Announced Date Jul 15, 2024; Funding Type Grant; Money Raised . obfuscated. obfuscated. Lead Investors. ... Apmonia …See details»
Apmonia Therapeutics announces a 4 M€ fundraising round
Feb 10, 2022 Apmonia Therapeutics announces a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01) …See details»
Apmonia Therapeutics (@ApmoniaTherap) / Twitter
Oct 10, 2022 Apmonia Therapeutics announced in feb 2022 a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP …See details»
Newsroom - Apmonia therapeutics
Sep 12, 2023 Apmonia Therapeutics to receive €2.5m grant and €7m equity investment from the European Innovation Council (EIC) as a laureate of the EIC Accelerator program. This major …See details»
Apmonia Therapeutics announces the launch of the …
Dec 5, 2022 Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week. We. READ MORE …See details»